CDC7 and head and neck squamous cell carcinoma: Furthermore, therapeutic inhibition of S-phase regulator CDC7, the function of which is essential for origin firing and replication fork formation [205], is currently clinically tested in a phase I trial with CDC7 inhibitor LY3143921 in HPV-negative HNSCC patients (NCT03096054).